Lilly's (LLY) Solanezumab Phase 3 Miss is Credit-Negative Event - Moody's
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Price: $1,213.91 +1.86%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.6%
EPS Growth %: +39.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.6%
EPS Growth %: +39.8%
Join SI Premium – FREE
Moody's Investor Service commented that Eli Lilly and Company's (NYSE: LLY) announcement that its experimental Alzheimer's disease drug solanezumab did not meet the endpoint in a Phase III trial is credit negative. There is no effect on Lilly's A2 rating or stable rating outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- HSBC Upgrades Power Asset Holdings (6:HK) (HGKGF) to Buy
- Morgan Stanley Resumes OMV AG (OMV:AV) (OMVKY) at Equalweight
Create E-mail Alert Related Categories
Credit RatingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
